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ElectrophoresisMonoclonal free light chains (FLCs) are important disease biomarkers in patients with plasma cell-proliferative
disorders. The increasing evidence for clonal diversity and evolution in multiple myeloma highlights the impor-
tance of laboratory algorithms that measure both intact immunoglobulins andmonoclonal FLCs, at diagnosis and
whenmonitoring response to treatment. A particular focus in theﬁeld has been on the utility of serumFLC (sFLC)
assays to replace urine electrophoresis for monoclonal FLCmeasurement. Due to the limited sensitivity and prac-
tical constraints of urine analysis, a serum-based algorithm of SPE and sFLC has been adopted bymany laborato-
ries as a ﬁrst line screen in patients with suspected monoclonal gammopathies. This reviewwill discuss the data
supporting the use of this simple serum-based algorithm at initial diagnosis, including its utility for the rapid
identiﬁcation of monoclonal FLC in the setting of unexplained acute kidney injury, and provide a comprehensive
review of the diagnostic sensitivity of sFLC in patients withmultiplemyeloma, AL amyloidosis and light chain de-
position disease.
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Open access under CC BY-NC-ND licen1. Introduction
Monoclonal immunoglobulin free light chains (FLC) are an important
diagnostic marker for monoclonal gammopathies and, for more than
150 years, the presence of Bence Jones protein (FLCs) in the urine has
been the key indicator of monoclonal FLC production. However, during
the last decade, there has been a paradigm shift with the availability
of automated immunoassays that independently measure kappa (κ)
and lambda (λ) FLC in the serum (Freelite®).
Serum concentrations of FLCs are dependent upon the balance be-
tween production and renal clearance. Serum FLCs (sFLCs) are rapidly
cleared through the renal glomeruli with half-lives of between 2 andse.
16 E. Jenner / Clinica Chimica Acta 427 (2014) 15–206 -h before being metabolised in the proximal tubules of the nephrons.
Under normal circumstances, little protein escapes to the urine so sFLC
concentrations are a more accurate representation of production levels.
When there is increased polyclonal immunoglobulin production and/or
renal impairment, both κ and λ sFLC concentrations can increase
30- to 40-fold. However, the relative concentrations of κ to λ (i.e.,
the κ/λ ratio) remain unchanged, or only slightly increase
(Section 2.2). In contrast, the production of a monoclonal excess of
one FLC type in patients with a plasma cell dyscrasia gives an abnormal
serum κ/λ ratio, providing a numerical indicator of clonality.
The clinical importance of sFLC assays for monoclonal gammopathies
is nowwell established, and their utility for the diagnosis, prognosis and
monitoring of these patients is acknowledged in national and interna-
tional guidelines [1–7]. This article will discuss the different laboratory
methods for the measurement of FLC and provide a comprehensive
review of the published data supporting the application of sFLC analysis
at diagnosis of monoclonal gammopathies, including the use of sFLC
assays to screen for nephrotoxic FLC in the setting of myeloma kidney.
2. Laboratory methods for the detection of monoclonal FLC
Laboratory methods to screen for monoclonal gammopathies histor-
ically comprise serum protein electrophoresis (SPE) and urine protein
electrophoresis (UPE). Monoclonal proteins (M-proteins) migrate as
discrete bands on an electrophoretic gel, appearing as a peak on a densi-
tometric trace, which provides a semi-quantitative value for the amount
of M-protein. Following the identiﬁcation of anM-protein by SPE, serum
immunoﬁxation electrophoresis (sIFE) is required for conﬁrmation
of clonality and subsequent typing. With an analytical sensitivity of be-
tween 500 and 2000 mg/L [8], a major limitation of SPE is the inability
to detect low-level monoclonal proteins, particularly FLCs. Serum IFE
is approximately 10-fold more sensitive and may pick up additional
monoclonal proteins that are undetected by SPE. However, the serum
of patients with oligosecretory diseases, such as light chain multiple
myeloma (LCMM), AL-amyloidosis and light chain deposition disease
(LCDD) often does not contain monoclonal FLCs at a level sufﬁcient
to be detected by either SPE or sIFE [9–11].
For over 150 years, monoclonal FLCs in the urine (Bence Jones
protein; BJP) have been an important diagnostic marker for multiple
myeloma (MM). UPE and urine IFE (uIFE) are more sensitive than
serum electrophoresis techniques for detecting monoclonal FLCs, and
FLCs can be detected in the urine at less than 20 mg/L, although most
laboratories claim an FLC detection limit of 40–50 mg/L.
Despite the additional sensitivity offered by UPE and uIFE, these
techniques are not without their technical and practical limitations.
First, FLC levels in the serummust increase signiﬁcantly before the prox-
imal tubular re-absorptive mechanisms are overwhelmed and the FLCs
appear in the urine. Nowrousian et al. [12] reported that the median
levels of monoclonal κ and λ FLC required in the serum before Bence
Jones proteinuria occurred were 113 mg/L and 278 mg/L, respectively.
Therefore, low-levelmonoclonal FLCs in the serummay not be detected
in the urine, and urine BJP tests are not a direct reﬂection of the under-
lying monoclonal FLC production rate. The second important consider-
ation for routine clinical practice is the delay associated with obtaining
a urine BJP result. The early detection of monoclonal FLC facilitates the
prompt diagnosis and timely initiation of treatment to improve clinical
outcome; however, delays can occur due to poor urine compliance, the
requirement for 24-h urine collection and batch testing of urine samples
by the laboratory. Studies have reported variable urine compliance
values of between 5% and 59% [13–17]. The third potential limitation
of urine based algorithms for the identiﬁcation of monoclonal FLCs is
the subjective interpretation of electrophoresis results. The detection of
low-level monoclonal FLCs is particularly problematic. ‘Ladder banding’
in concentrated urine samples may give the false impression
of monoclonality, and heavy proteinuria containing polyclonal FLCs
may give high background staining hindering accurate interpretation.Due to the highlighted limitations of urinalysis, international guidelines
now recommend that serum FLC testing replaces urine electrophoresis
in the diagnosis of monoclonal gammopathies [7].
2.1. Immunoassays for serum monoclonal FLC testing
In 2001, the availability of automated sFLC immunoassays (Freelite,
Binding Site, UK) has enabled routine and sensitive laboratory quanti-
ﬁcation of monoclonal FLC in the serum. The sFLC tests provide an
independent measurement of κ and λ FLC, and the calculation of a κ/λ
sFLC ratio provides a sensitive numerical indicator of clonality. In pa-
tients with plasma cell dyscrasias, the excess clonal production of only
one FLC type, frequentlywith bonemarrow suppression of the alternate
FLC, leads to often highly abnormal κ/λ ratios. The assays are latex-
enhanced immunoassays and allowmeasurement of FLC concentrations
as low as 1.5 mg/L and 3 mg/L for κ and λ FLCs, respectively, far below
normal serum concentrations [18]. The sFLC assays should not be
confused with total κ and λ light chain (TLC) assays, which detect all
forms of κ or λ light chains (FLC plus those that form intact immuno-
globulins). TLC assays are insensitive for the detection of sFLC [19] and
are not recommended by international guidelines.
It is essential that sFLC immunoassays utilise antibodies that have high
speciﬁcity and afﬁnity. For assays detecting homogeneous antigens,
monoclonal antibodies (Mabs) are very successful. However, a reliable
recognition of a full range of monoclonal FLC is hampered due to the
heterogeneity of FLC molecules, arising from a combination of genetic
recombination, allotypic and isotypic variation and somatic hyper-
mutation of the variable regions after antigen exposure. As a Mab will
only recognise a single epitope, individual Mabs will be unable to detect
the diverse range of monoclonal FLC produced by patients with mono-
clonal gammopathies. Hence, the Freelite assays were developed using
polyclonal antibodies, raised in sheep. These assays can recognise a
wide variety of FLC epitopes, including the diverse range of pathological
monoclonal FLC produced by patients with monoclonal gammopathies.
Several groups have developed Mab-based FLC immunoassays
[20–25]. A large number of clinical studies are still required to assess
their clinical utility, although published data has failed to demonstrate
their clinical equivalence to the established polyclonal assays [26,27].
International guidelines for sFLC measurement are based on results
obtained with Freelite, and the data discussed in this review has been
obtained using these polyclonal assays.
2.2. Interpretation of sFLC assay results at diagnosis
For sFLC analysis, both κ and λ FLCs should be measured and κ/λ ra-
tios calculated. Results are considered abnormal when they are outside
published normal ranges [18] (serum κ FLC: 3.3–19.4 mg/L; serum λ
FLC: 5.7–26.3 mg/L; serum κ/λ ratio: 0.26–1.65). If serum κ FLC, λ FLC
and κ/λ ratio are all within the normal ranges, and accompanying
serum electrophoretic tests are normal it is unlikely that the patient
has a monoclonal gammopathy. Conversely, abnormal κ/λ ratios,
along with an increase in either κ or λ FLC, support the diagnosis of a
monoclonal gammopathy and require further investigation, although
borderline results require careful interpretation. Borderline abnormal
κ/λ ratios can occasionally be seen in patients with polyclonal increases
in FLC, such as in patients with renal impairment, and in patients with
polyclonal hypergammaglobulinaemia, caused by for example infectious
or inﬂammatory disorders [28,29]. This highlights the importance of con-
sidering additional clinical and laboratory parameters when interpreting
sFLC results.
3. FLC incorporation into laboratory diagnostic panels for
monoclonal gammopathies
The utility of sFLC assays at diagnosis has been documented
for a broad spectrum of monoclonal plasma cell disorders, from the
Fig. 1. Dotplot of sFLC concentrations in patients with monoclonal gammopathies.
The normal 100% reference range for the sFLC κ/λ ratio (0.26–1.65) is represented by the
diagonal lines. Serum samples with abnormal κ/λ ratios lie outside of these lines. Normal
sera: red crosses; κ LCMM: black squares; λ LCMM: blue triangles; NSMM: green circles;
IIMM: blue diamonds; AL amyloidosis: yellow circles. Data adapted from [11,39,51].
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signiﬁcance (MGUS) and smouldering multiple myeloma (SMM)
to the symptomatic disorders multiple myeloma (MM), Waldenström's
macroglobulinaemia (WM), AL amyloidosis, LCDD, solitary plasma-
cytoma and POEMS. Numerous studies have evaluated the use of sFLC
assays alongside other laboratory tests as part of the initial diagnostic
screen for patients with a suspected monoclonal gammopathy
[13,15,17,28–33].
The most extensive study included 1877 patients (467 MM, 191
SMM, 524 MGUS, 29 plasmacytoma, 26 WM, 581 AL amyloidosis, 18
LCDD and 31 POEMS) who had a complete panel of SPE, sIFE, sFLC,
UPE and uIFE results obtained within 30 days of diagnosis [33]. When
comparing the combination of SPE and sFLC with SPE, sFLC and sIFE, 58
patients had a negative screen (44 MGUS, 7 POEMS, 5 AL amyloidosis,
1 plasmacytoma and 1 SMM). However, all MM,WM and LCDD patients
were detected. Furthermore, the addition of the sFLC assays identiﬁed 30
patients (23 AL amyloidosis, 6 MM and 1 LCDD) that were not detected
by the traditional panel of serum and urine tests. The omission of urine
analysis missed just 23 patients (15 MGUS, 1 extramedullary myeloma,
1 LCDD and 6 AL amyloidosis). As part of their conclusion, Katzmann
et al. stated that due to the small incremental sensitivity provided by
urine studies and sIFE, the use of SPEwith sFLC analysis provides a simple
and efﬁcient initial diagnostic screen for high tumour burden mono-
clonal gammopathies. They observed that urine studies and sIFE may
be ordered more selectively.
Based on the available published data, the International Myeloma
Working Group (IMWG) conclude that in the context of screening for
the presence of MM or related disorders, the sFLC assay in combination
with SPE and sIFE yields high sensitivity and negates the requirement
for 24-h urine studies for diagnosis other than for AL amyloidosis [7].
In their most recent guidelines, the IMWG recommend sFLC analysis as
part of the standard investigative workup in newly diagnosed patients
with plasma cell dyscrasias [6], a recommendation advocated in guide-
lines published by the US National Comprehensive Cancer Network
(NCCN) [1]. This also provides valuable prognostic information; the prog-
nostic utility of sFLC concentrations and ratios at disease presentation
and following treatment has been demonstrated by a number of groups
[34–37]. International guidelines recommend that the sFLC assay is
performed at diagnosis as a prognostic marker for all patients with MM,
as well as for patients with MGUS, SMM, solitary plasmacytoma and AL
amyloidosis [7].4. Diagnostic sensitivity of sFLC assays formonoclonal gammopathies
The frequency of abnormal sFLC κ/λ ratios that can be expected in
patients with MM (including light chain MM (LCMM), nonsecretory
MM(NSMM) and intact immunglobulinMM(IIMM)) andAL amyloidosis
is shown in Fig. 1.4.1. Light chain multiple myeloma
LCMM accounts for around 20% of all cases of MM. Its clinical diag-
nosis is conﬁrmed by the presence of monoclonal FLCs in the serum or
urine, in the absence of intact monoclonal immunoglobulins, alongside
clonal bone marrow plasma cells and the presence of end organ dam-
age. Screening with SPE alone may fail to detect over 40% of cases of
LCMM [38], and considering the limitations associated with detecting
monoclonal FLC in the urine, sFLC analysis forms an important part
of the diagnostic algorithm for these patients. All 224 patients with
LCMM in a study by Bradwell et al. [39] had abnormal concentrations
of the appropriate sFLC and abnormal κ/λ ratios at the time of diagnosis
(Fig. 1). The same 100% diagnostic sensitivity of sFLC ratios for LCMM
has been found in numerous studies, which, in total, have included
over 600 patients [12,16,28,38–45].4.2. Nonsecretory multiple myeloma
Accounting for 1–5% of all MM patients, NSMM is characterised
by the absence of monoclonal proteins in serum and urine by IFE
[9,10,46,47]. However, some NSMM patients produce monoclonal
immunoglobulins that, despite being undetected in the serum, can
be detected immunohistochemically in bone marrow plasma cells,
and it is considered that only 10–15% of NSMM patients are true ‘non-
producers’ [48], in whom tumour plasma cells contain no detectable
immunoglobulins.
The sensitivity of sFLC immunoassays has proved particularly
beneﬁcial for detecting monoclonal FLCs in patients previously
deemed nonsecretory according to electrophoresis. In a study of
28 NSMM patients [10], 68% had elevated κ or λ sFLC concentrations
and abnormal κ/λ ratios (Fig. 1). Surprisingly, in 9 of the 28 patients, no
monoclonal bands were seen by IFE even though the immunoassays
indicated sFLC concentrations of N200 mg/L, greater than the detection
limit of IFE. Further investigation of 2 samples (with 931 mg/L and
978 mg/L monoclonal κFLC) revealed polymerised FLC, which act as
multi-antigenic targets in immunoassays, leading to overestimation
of antigen concentrations, and could also account for their absence
or diffuse appearance by IFE.
Measurement of sFLC at diagnosis for many NSMM patients has
produced clear beneﬁts for the patient, avoiding diagnostic delays
[49], and sFLC analysis is therefore recommended by the IMWG for
patients with NSMM [7].
4.3. Intact immunoglobulin multiple myeloma
IIMM comprises around 80% of all cases of MM. Since this type of
MM is characterised by the secretion of monoclonal intact immuno-
globulins, SPE and sIFE play an essential role in the diagnosis of these
patients. However, in around 95% of patients with IIMM monoclonal
FLCs are also secreted [33,36,50–52]. In these patients, the utility of
sFLC analysis lies in disease monitoring and patient prognosis. The
short serumhalf-life of FLCsmake themusefulmarkers of clonal disease
and the monitoring of monoclonal sFLC levels can provide a more accu-
rate assessment of the rate of treatment responses than that provided
18 E. Jenner / Clinica Chimica Acta 427 (2014) 15–20by intact immunoglobulins, whose half-lives are considerably longer
[53].
Importantly, the serological diagnosis of disease relapse in IIMM pa-
tients cannot be relied upon by measuring monoclonal intact immuno-
globulins alone. Clonal evolution inMM is increasingly being recognised
[2,54–57] and is associated with a change in the monoclonal protein(s)
being produced. For example, patients with IIMM at diagnosis may
relapse with monoclonal FLCs only, a phenomenon termed light chain
escape [58,59] (Fig. 2). Due to high monoclonal FLC concentrations,
these patients are prone to renal complications, and regular assessment
of sFLCs during patientmonitoring can provide early indications of renal
impairment and any risk of renal failure. In light of the complex clonal
dynamics involved in MM, it is advisable that both monoclonal intact
immunoglobulins and sFLCs are measured. Interestingly, one study
demonstrated that the monoclonal protein type in patients with LCMM
does not alter at disease relapse [59] (Fig. 2).
4.4. AL amyloidosis and light chain deposition disease
AL amyloidosis and LCDD are two disorders caused by the extra-
cellular precipitation of monoclonal light chains which disrupt the
structure and function of multiple organs. In AL amyloidosis, light chain
fragments, most commonly λ type, accumulate as insoluble amyloid
ﬁbrils and frequently affect the kidney and heart. The monoclonal light
chains most often involved in LCDD are κ type and are precipitated
on the basement membranes of cells in the kidneys and various
other organs. While a deﬁnitive diagnosis of AL amyloidosis or
LCDD is established by a tissue biopsy and histological examination,
the detection of the monoclonal protein provides important supportive
evidence of an underlying plasma cell dyscrasia.
Studies evaluating the diagnostic performance of the sFLC ratio in AL
amyloidosis have documented a diagnostic sensitivity ranging from75%
to 98% [11,33,60–64]. The observation that an abnormal sFLC ratio has a
greater diagnostic sensitivity than the combination of serum or urine
IFE (98% vs. 79%) [11] has been supported by some studies [60] but
not by others [61–63]. However, in all published studies to date, sFLC
analysis has proven to be an important complementary technique to
electrophoresis,which is reﬂected in IMWGguidelines that recommend
sFLC analysis alongside sIFE and uIFE to screen patients with suspected
AL amyloidosis [7]. Abnormal sFLC ratios are also found in 88–100% of
patientswith LCDD, ofwhich approximately 1/3 of patients are negative
by sIFE [33,65,66]. As such, sFLC analysis is a useful addition to electro-
phoretic tests when screening for and monitoring LCDD and is recom-
mended by the IMWG [7].Fig. 2. Changes in monoclonal protein type at relapse or progression of disease (R/POD).
Reprinted with permission from Macmillan Publishers Ltd, nature.com [59].5. Serum FLC assays for early detection of myeloma kidney
The clonal production of nephrotoxic FLCs is the predominant
cause of the renal injury associated with MM and related monoclonal
gammopathies. Monoclonal FLCs can induce a number of different
pathologies within the kidney, which in turn can result in different clin-
ical presentations. Of these, the most common presentation of FLC-
induced renal injury is acute kidney injury (AKI) secondary to the tubu-
lar interstitial pathology cast nephropathy. In cast nephropathy, also
known as myeloma kidney, waxy casts form in the distal tubules of
the nephron due to the aggregation of FLC with Tamm Horsfall protein,
causing interstitial inﬂammation and ﬁbrosis. Found in approximately
90% of dialysis-dependent MM patients [16], myeloma kidney is the
most common cause of AKI in MM.
A timely diagnosis is critically important in order to initiate treatment
regimens to rapidly reduce FLC concentrations in patientswithmyeloma
kidney. Such early FLC reductions are associated with improved survival
[67]. Therefore, a screening algorithm designed to enable the rapid diag-
nosis of myeloma kidney as the cause of AKI has recently been proposed
by the International Kidney and Monoclonal Gammopathy Research
Group [68]. This algorithm proposes that the ﬁrst priority in assessing a
patient with unexplained AKI is to determine if monoclonal FLCs are
present. To enable this, either sFLC assays or uIFE can be utilised, but
given the limitations of urine analyses described in Section 2, many lab-
oratories now use sFLC assays ﬁrst line.Whenmonoclonal FLCs are pres-
ent, the serum concentration of the involved FLCs can provide signiﬁcant
guidance as to the likelihood of myeloma kidney as the renal pathology.
Patients with myeloma kidney have baseline monoclonal sFLC concen-
trations that are typically above 500 mg/L [16,67,69–74], and a cutoff of
500 mg/L is commonly used as the level above which cast nephropathy
is the likely pathology. A small number of patients with a high con-
centration of monoclonal FLC may have an alternative diagnosis to
cast nephropathy [75] and so a renal biopsy should be considered
for conﬁrmation.6. Conclusion
The incorporation of sFLC assays into diagnostic algorithms for plasma
cell disorders had led to a paradigm shift in the understanding of these
diseases. There has been a particular focus on the utility of sFLC analysis
in AL amyloidosis, LCMM and NSMM, and recently for the rapid identiﬁ-
cation of myeloma kidney as a cause of unexplained AKI. As it becomes
increasingly understood that MM is a multi-clonal disease, moving for-
ward it is likely that serum-based tests for the measurement of mono-
clonal FLCs will become a greater adjunct to traditional measurements
to identify all clones and monitor clonal evolution in patients with MM.Acknowledgements
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